That said, our data are consistent with prior reports describing the inhibitory potential of dual CDK12/13 inhibitor ZSQ836 in HEY and SKOV3 ovarian cancer cell lines and THZ531 in patient-derived ovarian cancer organoids (20, 21). The gene discussed is CDK12; the disease is ovarian carcinoma.